TRCT
OASM

Tower Research Capital (TRC)’s Oasmia Pharmaceutical AB OASM Stock Holding History

Tower Research Capital (TRC)’s Portfolio OASM Stock Details OASM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-153
Closed – – 4344
2016
Q4 		$0 Sell
153
-647
-81% -$1.91K ﹤0.01% 4721
2016
Q3 		$2K Hold
800
– – ﹤0.01% 3191
2016
Q2 		$3K Sell
800
-4
-0.5% -$17 ﹤0.01% 3794
2016
Q1 		$3K Buy
804
+800
+20,000% +$2.83K ﹤0.01% 3228
2015
Q4 		$0 Buy
+4
New +$16 ﹤0.01% 5374

Other funds holding OASM

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Tower Research Capital (TRC)'s OASM Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Oasmia Pharmaceutical AB (OASM) in Q1 2017, closing a stake of 153 shares.

Tower Research Capital (TRC) first reported a position in OASM in Q4 2015 and held it in 5 quarters. The position peaked at $3K in Q2 2016. 3 funds tracked by Wall St. Rank hold OASM as of Q1 2017.

  • Tower Research Capital (TRC) reported no remaining Oasmia Pharmaceutical AB position as of Q1 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 153 Oasmia Pharmaceutical AB shares in Q1 2017.
  • Tower Research Capital (TRC) first reported a position in Oasmia Pharmaceutical AB in Q4 2015 and held it in 5 quarters.
  • Tower Research Capital (TRC)'s Oasmia Pharmaceutical AB position peaked at $3K in Q2 2016.
  • 3 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.